MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Pluristem Therapeutics Long Term Debt Current 2011-2026 | PSTI
Annual Long Term Debt Current Pluristem Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 659 K | 559 K | 627 K | 619 K | 634 K | 1.02 M | - | - | - | - | - | - | - | 13 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.02 M | 13 K | 590 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M |  USA |
 |
Veracyte
VCYT
|
4.05 M | $ 31.01 | -5.46 % | $ 2.44 B | USA |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Vir Biotechnology
VIR
|
8.8 M | $ 8.47 | -5.47 % | $ 1.17 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Viking Therapeutics
VKTX
|
137 K | $ 32.67 | -4.61 % | $ 3.68 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | USA |
 |
Viridian Therapeutics
VRDN
|
753 K | $ 27.39 | -2.87 % | $ 2.79 B | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
77.3 M | $ 437.99 | -3.47 % | $ 112 B | USA |
 |
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Verastem
VSTM
|
535 K | $ 5.01 | -5.29 % | $ 347 M | USA |
 |
VistaGen Therapeutics
VTGN
|
561 K | $ 0.56 | -7.23 % | $ 17.3 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 12.88 | -7.74 % | $ 1.95 B | USA |
 |
vTv Therapeutics
VTVT
|
154 K | $ 38.69 | 2.35 % | $ 152 M | USA |
 |
Voyager Therapeutics
VYGR
|
7.84 M | $ 3.97 | -4.0 % | $ 233 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 320.49 | -2.34 % | $ 42 B | USA |
 |
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
363 K | $ 1.93 | -6.31 % | $ 111 M | USA |
 |
Amgen
AMGN
|
135 M | $ 351.01 | -0.61 % | $ 189 B | USA |